Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,446 total articles
BridgeBio Pharma announced FDA acceptance of its New Drug Application for encaleret, a potential disease-modifying oral therapy for autosomal dominant hypocalcemia type 1 (ADH1). The FDA set a PDUFA date of May 8, 2027, and the company is prepared for launch upon approval. Encaleret has shown positive Phase 3 results, with potential to transform ca…
Prairie Operating Co., a Nasdaq-listed independent energy company focused on oil and natural gas development in the Denver-Julesburg Basin, announced the appointment of Jennifer M. Grigsby to its Board of Directors. This move coincides with Stephen Lee stepping down from the Board to concentrate on his role at Renewa. Grigsby brings extensive exper…
Zevra Therapeutics, a commercial-stage biopharmaceutical company specializing in rare diseases, announced it will release its second quarter 2026 financial results after market close on August 5, 2026, followed by a conference call and webcast. The company focuses on advancing therapies for rare diseases such as Niemann-Pick disease type C and expa…
Trinity Biotech plc plans to change its ADS ratio from one ADS representing 20 Class A ordinary shares to one ADS representing 600 Class A ordinary shares. This reverse ADS split aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement and broaden the investor base by increasing the ADS price. The change will take effect on July …
SOLV Energy, a provider of infrastructure services to the power industry, announced it will report its second quarter 2026 financial results on August 13, 2026, followed by a management conference call. The company serves the power sector with EPC, O&M, repowering, and SCADA services, managing a significant portfolio of power plants.
Radiopharm Theranostics announced encouraging Phase 1 clinical trial results for RAD204, a PD-L1-targeted radiotherapeutic in development for advanced solid tumors post-immunotherapy. The first two patients at the highest dose showed durable partial tumor responses and remain progression-free, with RAD204 exhibiting a favorable safety profile and n…
Royalty Pharma has secured a significant royalty interest in AstraZeneca's cliramitug, a promising Phase 3 therapy targeting transthyretin amyloidosis with cardiomyopathy (ATTR-CM), by acquiring part of Neurimmune’s royalty rights for up to $425 million. Cliramitug represents a first-in-class approach aimed at removing amyloid deposits rather than …
uniQure N.V., a gene therapy company specializing in transformative treatments, announced it will release its second quarter 2026 financial results before market open on July 29, 2026, followed by a management conference call. The company highlighted its approval for gene therapy in hemophilia B and ongoing development for other severe diseases.
Oatly Group AB reported second quarter 2026 financial results with revenue of $240.1 million, a 15.2% increase year-over-year, driven by strong growth in Europe, North America, and Greater China. The company improved gross margin to 33.9% and narrowed net loss to $31.3 million from $55.9 million a year ago. Adjusted EBITDA improved to a slight posi…
Stifel Financial Corp. reported net revenues of $1.45 billion and net income of $217.2 million for Q2 2026, marking the best second quarter in company history. Significant growth was driven by increased investment banking revenues, asset management, and commission revenues. The company also achieved record client assets, improved operating leverage…
Advantage Solutions Inc., a leading omnichannel retail solutions agency, will report its second quarter 2026 financial results on August 5, 2026, followed by a conference call and webcast for investors and interested parties. The company provides data and technology-powered services to consumer-packaged goods brands and retailers to drive demand an…
Rogers Communications released its Q2 2026 results showing strong growth in total service revenue (+8%) and adjusted EBITDA (+3%), with stable wireless revenue and growth in cable and media segments. The company completed an agreement to acquire the remaining 25% stake in Maple Leaf Sports & Entertainment, positioning it for further sports monetiza…
Fidelity D & D Bancorp, Inc. reported robust second quarter and first half 2026 results, with net income increasing 13% in Q2 and 19% year-over-year. Growth was driven primarily by a substantial increase in net interest income due to higher loan balances and improved yields, alongside modest increases in non-interest income, particularly from wealt…
Avalo Therapeutics, a clinical-stage biotech focused on IL-1β pathway therapeutics for immune-mediated inflammatory diseases, announced CEO participation in a BTIG Biotechnology Conference panel and one-on-one investor meetings. The company recently reported positive Phase 2 data for its lead candidate, abdakibart, in hidradenitis suppurativa and i…
Geron Corporation, a commercial-stage biopharmaceutical company specializing in blood cancer treatments, announced it will release its Q2 2026 financial results and business highlights on August 5, 2026. The company will host a conference call and webcast to discuss the results. Geron focuses on its telomerase inhibitor drug RYTELO® (imetelstat), a…
Coherent Corp., a leader in photonics technology, announced it will release its financial results for Q4 and fiscal year 2026 on August 12, 2026, after the NYSE closes, followed by a live webcast to discuss the results. The company highlights its position across data center, communications, and industrial markets, supporting ongoing innovation.
OKYO Pharma's Chief Medical Officer, Dr. Flavio Mantelli, has purchased 20,000 shares of the company at $1.40 per share. This insider buying occurs as the company prepares to initiate a global Phase 3 clinical trial for urcosimod, targeting neuropathic corneal pain. The move signals confidence in the upcoming pivotal study and the company’s therape…
Standard BioTools Inc., a life science tools company listed on NASDAQ under the ticker LAB, announced it will release its second quarter 2026 financial results after the U.S. market closes on August 5, 2026. The company specializes in providing standardized next-generation solutions to biomedical researchers to accelerate therapeutic development.
AmpliTech Group announced that its new Outdoor Macro Cell 4T8R Open RAN Radio Unit has received FCC approval in the U.S. and ISED certification in Canada, enabling deployment across North America. The AI-ready 4T8R architecture offers improved network performance and cost efficiency, positioning AmpliTech to capitalize on expanding 5G, Open RAN mod…
Radiopharm Theranostics announced positive Phase 2b trial results for RAD101, a novel PET imaging agent targeting fatty acid synthase, demonstrating 93% concordance with MRI and 86% sensitivity in detecting recurrent brain metastases. The company plans to initiate a US Phase 3 pivotal trial in Q4 2026, addressing a significant unmet need in neuro-o…
BioCryst Pharmaceuticals, a US-based biotechnology company specializing in treatments for rare diseases like hereditary angioedema, announced it will report its second quarter 2026 financial results on August 5, 2026. The company plans to host a conference call and webcast to discuss the results and provide a corporate update.
NOVAGOLD RESOURCES INC. announced an all-share transaction to acquire Paulson's 40% stake in Donlin Gold, increasing NOVAGOLD's ownership to 100%. The new entity, NovaGold Corporation, will be U.S.-domiciled and listed on NYSE, consolidating control to streamline development and financing of Donlin Gold—projected to be the largest gold mine in the …
Old National Bancorp, a top 25 U.S. bank, reported record second quarter 2026 net income applicable to common shares of $249.4 million with diluted EPS of $0.65, driven by strong loan growth, stable net interest margin, disciplined expense management, and robust credit quality. The company also announced an enhanced executive leadership structure t…
Pharvaris, a Nasdaq-listed late-stage biopharmaceutical company, announced a publication in Clinical Reviews in Allergy & Immunology providing an in-depth review of the bradykinin B2 receptor's role in bradykinin-mediated angioedema and other immunological diseases. The article consolidates decades of research supporting the bradykinin B2 receptor …
Repligen Corporation is acquiring BioLife Solutions for approximately $1.5 billion to strengthen its position in the rapidly growing cell therapy market. The transaction, consisting of 64% stock and 36% cash, will add BioLife's differentiated biopreservation media products and expand Repligen's offerings with high-margin recurring revenue assets. T…
